Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues.

Bhatt, S; Kanoujia, J; Mohanalakshmi, S; Patil, CR; Gupta, G; Chellappan, DK; Dua, K

Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues.

Bhatt, S Kanoujia, J Mohanalakshmi, S Patil, CR Gupta, G Chellappan, DK Dua, K

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: CNS Neurol Disord Drug Targets, 2022, 21
Issue Date:: 2022-03-29

Closed Access

	Filename	Description	Size
	Brain-Gut axis_Depression_35352640.pdf	Published version	2.44 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Bhatt, S
dc.contributor.author	Kanoujia, J
dc.contributor.author	Mohanalakshmi, S
dc.contributor.author	Patil, CR
dc.contributor.author	Gupta, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2022-07-13T15:16:48Z
dc.date.available	2022-01-25
dc.date.available	2022-07-13T15:16:48Z
dc.date.issued	2022-03-29
dc.identifier.citation	CNS Neurol Disord Drug Targets, 2022, 21
dc.identifier.issn	1871-5273
dc.identifier.issn	1996-3181
dc.identifier.uri	http://hdl.handle.net/10453/158864
dc.description.abstract	The human gut microbiota plays a significant role in the pathophysiology of central nervous system related diseases. Recent studies suggest correlations between the altered gut microbiota and major depressive disorder (MDD). It is proposed that normalization of the gut microbiota alleviates MDD. The imbalance of brain-gut-microbiota axis also results in dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. This imbalance has a crucial role in the pathogenesis of depression. Treatment strategies with certain antibiotics lead to the depletion of useful microbes and thereby induce depression like effects in subjects. Microbiota is also involved in the synthesis of various neurotransmitters (NTs) like 5-hydroxy tryptamine (5-HT; serotonin), norepinephrine (NE) and dopamine (DA). In addition to NTs, the gut microbiota also has influence on brain derived neurotrophic factor (BDNF) levels. Recent research findings have exhibited that transfer of stress prone microbiota in mice is also responsible for depression and anxiety-like behaviour in animals. The use of probiotics, prebiotics, synbiotics and proper diet have shown the beneficial effects in the regulation of depression pathogenesis. Moreover, transplantation of fecal microbiota from depressed individuals to the normal subjects also induces depression like symptoms. With the precedence of limited therapeutic benefits from monoamine targeting drugs, the regulation of brain-gut microbiota is emerging as a new treatment modality for MDDs. In this review, we elaborate the significance of brain-gut-microbiota axis in the progression of MDD, particularly focusing on the modulation of the gut microbiota as a mode of treating MDD.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	CNS Neurol Disord Drug Targets
dc.relation.isbasedon	10.2174/1871527321666220329140804
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1109 Neurosciences, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Neurology & Neurosurgery
dc.title	Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues.
dc.type	Journal Article
utslib.citation.volume	21
utslib.location.activity	United Arab Emirates
utslib.for	1109 Neurosciences
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-07-13T15:16:46Z
pubs.publication-status	Published online
pubs.volume	21

Abstract:

The human gut microbiota plays a significant role in the pathophysiology of central nervous system related diseases. Recent studies suggest correlations between the altered gut microbiota and major depressive disorder (MDD). It is proposed that normalization of the gut microbiota alleviates MDD. The imbalance of brain-gut-microbiota axis also results in dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. This imbalance has a crucial role in the pathogenesis of depression. Treatment strategies with certain antibiotics lead to the depletion of useful microbes and thereby induce depression like effects in subjects. Microbiota is also involved in the synthesis of various neurotransmitters (NTs) like 5-hydroxy tryptamine (5-HT; serotonin), norepinephrine (NE) and dopamine (DA). In addition to NTs, the gut microbiota also has influence on brain derived neurotrophic factor (BDNF) levels. Recent research findings have exhibited that transfer of stress prone microbiota in mice is also responsible for depression and anxiety-like behaviour in animals. The use of probiotics, prebiotics, synbiotics and proper diet have shown the beneficial effects in the regulation of depression pathogenesis. Moreover, transplantation of fecal microbiota from depressed individuals to the normal subjects also induces depression like symptoms. With the precedence of limited therapeutic benefits from monoamine targeting drugs, the regulation of brain-gut microbiota is emerging as a new treatment modality for MDDs. In this review, we elaborate the significance of brain-gut-microbiota axis in the progression of MDD, particularly focusing on the modulation of the gut microbiota as a mode of treating MDD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/158864